Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...